Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
International Journal of Hematology · 2024
DOI: 10.1007/s12185-024-03850-9 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Souichi Shiratori und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Graft vs Host Disease, Nitriles, Pyrazoles, Pyrimidines. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis.
Abstract (Originalsprache)
Ruxolitinib, a Janus kinase (JAK1–JAK2) inhibitor, has demonstrated safety and efficacy in patients with graft-versus-host disease (GvHD). This phase 3 randomized trial (REACH3) evaluated the efficacy and the safety of ruxolitinib 10 mg twice daily compared with investigator-selected best available therapy (BAT) in a subgroup of Japanese patients ( n = 37) with steroid-refractory or dependent (SR/D) chronic GvHD. At data cut-off, treatment was ongoing in 17 patients and discontinued in 20. The overall response rate (complete or partial) at week 24 was greater with ruxolitinib than BAT (50% vs. 20%; odds ratio, 4.13 [95% CI, 0.90–18.9]). The best overall response rate (complete or partial response at any time point up to week 24) was higher with ruxolitinib than BAT (68.2% vs. 46.7%; odds ratio, 2.69 [95% CI, 0.66–10.9]). Ruxolitinib led to longer median failure-free survival than BAT (18.6 months vs. 3.7 months; hazard ratio, 0.34; [95% CI, 0.14–0.85]). The most common grade ≥ 3 adverse events up to week 24 were anemia (ruxolitinib: 22.7%; BAT: 6.7%) and pneumonia (22.7% and 20.0%, respectively). Ruxolitinib showed a higher response rate and improvement in failure-free survival in Japanese patients with SR/D chronic GvHD, with a safety profile consistent with the overall study population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Hematology, Tohoku University Hospital, Miyagi, Japan.
- Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Aichi, Japan.
- Hyogo College of Medicine, Kansai Medical University Medical Center, Hyogo, Japan.
Förderung
- Novartis
Zitieren
APA
Shiratori, S., Fukushima, K., Onishi, Y., Doki, N., Goto, T., Okada, M., Nakamae, H., Maeda, Y., Kato, K., Ishikawa, T., Kondo, T., Toyosaki, M., Ikeda, T., Uchida, N., Maki, A., Shimada, F., Tajima, T., Stefanelli, T., & Teshima, T. (2024). Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03850-9
Vancouver
Shiratori S, Fukushima K, Onishi Y, Doki N, Goto T, Okada M, et al. Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03850-9
BibTeX
@article{Shiratori2024,
author = {Shiratori, Souichi and Fukushima, Kentaro and Onishi, Yasushi and Doki, Noriko and Goto, Tatsunori and Okada, Masaya and Nakamae, Hirohisa and Maeda, Yoshinobu and Kato, Koji and Ishikawa, Takayuki and Kondo, Tadakazu and Toyosaki, Masako and Ikeda, Takashi and Uchida, Naoyuki and Maki, Akio and Shimada, Fumika and Tajima, Takeshi and Stefanelli, Tommaso and Teshima, Takanori},
title = {Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study},
journal = {International Journal of Hematology},
year = {2024},
doi = {10.1007/s12185-024-03850-9}
}
EUVIMED